EpiCept Corporation (Nasdaq: EPCT) 18.9% HIGHER; today announced that the National Cancer Institute has initiated a Phase II trial with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE